异基因造血细胞移植中的酪氨酸激酶抑制剂与免疫检查点阻断
综述探讨酪氨酸激酶抑制剂(靶向bcr-abl、FLT3)与免疫检查点抑制剂(阻断CTLA4和PD-1)在异基因造血细胞移植围移植期及移植后的免疫学与临床后果,指出这些药物在预防或治疗复发方面显示潜在疗效但确定性证据仍缺乏,潜在毒性可能相当大,需进一步临床试验明确治疗窗。
要点
- 靶向bcr-abl和FLT3的酪氨酸激酶抑制剂及阻断CTLA4和PD-1的免疫检查点抑制剂在allo-HCT中显示潜在防复发疗效。
- 确定性证据仍缺乏,潜在毒性可能相当大。
- 需进一步临床试验明确这些药物在allo-HCT中的治疗窗。
核心结论
- 酪氨酸激酶抑制剂和免疫检查点抑制剂在异基因造血细胞移植围移植期及移植后显示潜在预防或治疗复发的疗效,但确定性证据仍缺乏,潜在毒性可能相当大,需进一步临床试验明确治疗窗。
研究设计与样本
- 综述,探讨酪氨酸激酶抑制剂与免疫检查点抑制剂在异基因造血细胞移植围移植期及移植后的免疫学与临床后果。
主要发现
- 过去十年中,移植物抗宿主病(GVHD)和机会性感染预防的进展改善了异基因造血细胞移植(allo-HCT)后的生存。
- 在治疗或预防allo-HCT所针对的恶性肿瘤复发方面进展甚少。
- 美国食品药品监督管理局批准的多种血液系统恶性肿瘤活性药物为在allo-HCT背景下评估这些干预提供了机会。
- 最有前景的新药包括靶向bcr-abl的酪氨酸激酶抑制剂(TKIs)、靶向fms样酪氨酸激酶3的激酶抑制剂以及阻断CTLA4和PD-1的免疫检查点抑制剂。
- 数据表明这些药物在预防或治疗复发方面具有潜在疗效,但确定性证据仍缺乏,潜在毒性可能相当大。
局限性
- 确定性证据仍缺乏。
- 潜在毒性可能相当大。
- 需进一步临床试验明确治疗窗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in the prevention of graft-versus-host disease (GVHD) and opportunistic infection have improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) in the past decade. However, few inroads have been made into the treatment or prevention of relapse of the underlying malignancy for which allo-HCT is being performed. The introduction of US Food and Drug Administration-approved agents with significant activity in a variety of hematologic malignancies provides an opportunity to evaluate these interventions in the allo-HCT setting. Some of the most promising new agents include tyrosine kinase inhibitors (TKIs) directed at bcr-abl, kinase inhibitors targeting fms-like tyrosine kinase 3, and immune checkpoint inhibitors blocking both CTLA4 and PD-1. Data have emerged indicating potential efficacy of these agents in preventing or treating relapse, though definitive evidence remains elusive. However, potential toxicity can be considerable, highlighting the need for further clinical trials to define the therapeutic window. This review explores the immunologic and clinical consequence of treatment with both TKIs and checkpoint inhibitors in the peri- and post-allo-HCT setting.
引用
- Soiffer RJ, Davids MS, Chen YB, et al. Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood. 2018. PMID: 29358177. doi:10.1182/blood-2017-10-752154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。